{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aspirin+%28ASA%29&page=20",
    "query": {
      "intervention": "Aspirin (ASA)",
      "page": 20
    },
    "page_size": 10
  },
  "pagination": {
    "page": 20,
    "page_size": 10,
    "total_count": 588,
    "total_pages": 59,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aspirin+%28ASA%29&page=21&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aspirin+%28ASA%29&page=19&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T20:06:09.704Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00300365",
      "title": "Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metabolic Syndrome"
      ],
      "interventions": [
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Niacin ER",
          "type": "DRUG"
        },
        {
          "name": "Aspirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 38,
      "start_date": "2005-11",
      "completion_date": "2010-08",
      "has_results": true,
      "last_update_posted_date": "2017-07-28",
      "last_synced_at": "2026-10-15T20:06:09.704Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00300365"
    },
    {
      "nct_id": "NCT01817400",
      "title": "Mediators of Abnormal Reproductive Function in Obesity (MARO)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Infertility, Female",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Microdialysis",
          "type": "OTHER"
        },
        {
          "name": "Vascepa - Fish Oil",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Aspirin",
          "type": "DRUG"
        },
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DIETARY_SUPPLEMENT",
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 60 Years · Female only"
      },
      "enrollment_count": 10,
      "start_date": "2013-03",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2015-03-17",
      "last_synced_at": "2026-10-15T20:06:09.704Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01817400"
    },
    {
      "nct_id": "NCT01432600",
      "title": "Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Myeloma"
      ],
      "interventions": [
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2011-11",
      "completion_date": "2016-08",
      "has_results": true,
      "last_update_posted_date": "2017-05-23",
      "last_synced_at": "2026-10-15T20:06:09.704Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Tampa, Florida • New York, New York",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01432600"
    },
    {
      "nct_id": "NCT05031455",
      "title": "Mechanisms of Dupilumab in AERD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Aspirin-exacerbated Respiratory Disease"
      ],
      "interventions": [
        {
          "name": "Aspirin Challenge",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Scripps Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2024-03-25",
      "completion_date": "2026-04-20",
      "has_results": false,
      "last_update_posted_date": "2026-04-28",
      "last_synced_at": "2026-10-15T20:06:09.704Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05031455"
    },
    {
      "nct_id": "NCT00467363",
      "title": "The Effects of Aspirin in Gestation and Reproduction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Birth",
        "Spontaneous Abortion"
      ],
      "interventions": [
        {
          "name": "acetylsalicylic-acid (aspirin)",
          "type": "DRUG"
        },
        {
          "name": "Folic acid",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 1228,
      "start_date": "2007-06",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2017-02-03",
      "last_synced_at": "2026-10-15T20:06:09.704Z",
      "location_count": 4,
      "location_summary": "Denver, Colorado • Buffalo, New York • Scranton, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Scranton",
          "state": "Pennsylvania"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00467363"
    },
    {
      "nct_id": "NCT02123849",
      "title": "Intermittent or Continuous Acetylsalicylic Acid and Gene Expression in the Nasal Tissue of Current Smokers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Carcinoma",
        "Tobacco Use Disorder"
      ],
      "interventions": [
        {
          "name": "Aspirin",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2014-06",
      "completion_date": "2018-02",
      "has_results": true,
      "last_update_posted_date": "2018-08-29",
      "last_synced_at": "2026-10-15T20:06:09.704Z",
      "location_count": 2,
      "location_summary": "Tucson, Arizona • Boston, Massachusetts",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02123849"
    },
    {
      "nct_id": "NCT02504216",
      "title": "Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Peripheral Artery Disease"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban-Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 6564,
      "start_date": "2015-08-18",
      "completion_date": "2020-01-09",
      "has_results": true,
      "last_update_posted_date": "2020-12-08",
      "last_synced_at": "2026-10-15T20:06:09.704Z",
      "location_count": 105,
      "location_summary": "Alexander City, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 91 more",
      "locations": [
        {
          "city": "Alexander City",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fort Payne",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Avondale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02504216"
    },
    {
      "nct_id": "NCT03667326",
      "title": "Postpartum Low-Dose Aspirin and Preeclampsia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Preeclampsia Postpartum"
      ],
      "interventions": [
        {
          "name": "Aspirin tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 100,
      "start_date": "2019-07-22",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-10-15T20:06:09.704Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03667326"
    },
    {
      "nct_id": "NCT01830543",
      "title": "A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atrial Fibrillation",
        "Percutaneous Coronary Intervention"
      ],
      "interventions": [
        {
          "name": "rivaroxaban 2.5 mg",
          "type": "DRUG"
        },
        {
          "name": "rivaroxaban 15 mg",
          "type": "DRUG"
        },
        {
          "name": "rivaroxaban 10 mg",
          "type": "DRUG"
        },
        {
          "name": "aspirin (ASA)",
          "type": "DRUG"
        },
        {
          "name": "vitamin K antagonist (VKA)",
          "type": "DRUG"
        },
        {
          "name": "clopidogrel",
          "type": "DRUG"
        },
        {
          "name": "prasugrel",
          "type": "DRUG"
        },
        {
          "name": "ticagrelor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Scientific Affairs, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2124,
      "start_date": "2013-05-10",
      "completion_date": "2016-07-28",
      "has_results": true,
      "last_update_posted_date": "2017-09-19",
      "last_synced_at": "2026-10-15T20:06:09.704Z",
      "location_count": 86,
      "location_summary": "Huntsville, Alabama • Los Alamitos, California • Mission Viejo, California + 83 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01830543"
    },
    {
      "nct_id": "NCT02846532",
      "title": "Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Thrombosis"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        },
        {
          "name": "Acetylsalicylic Acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "8 Years",
        "sex": "ALL",
        "summary": "2 Years to 8 Years"
      },
      "enrollment_count": 112,
      "start_date": "2016-11-16",
      "completion_date": "2020-07-16",
      "has_results": true,
      "last_update_posted_date": "2025-03-30",
      "last_synced_at": "2026-10-15T20:06:09.704Z",
      "location_count": 17,
      "location_summary": "Los Angeles, California • Gainesville, Florida • Oak Lawn, Illinois + 14 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Oak Lawn",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02846532"
    }
  ]
}